Cardiomyopathy in murine models of systemic sclerosis

Arthritis and Rheumatology

Volumn 67, Issue 2, 2015, Pages 508-516

  Venalis, Paulius ^a,b,c   Kumánovics, Gábor ^d   Schulze Koops, Hendrik ^e   Distler, Alfiya ^c   Dees, Clara ^c   Zerr, Pawel ^c   Palumbo Zerr, Katrin ^c   Czirják, Lászlõ ^d   Mackevic, Zygmunt ^f   Lundberg, Ingrid E ^a,b   Distler, Oliver ^g   Schett, Georg ^c   Distler, Jörg H W ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF PÉCS   (Hungary)

^e UNIVERSITY OF MUNICH   (Germany)

^f State Research Institute Centre for Innovative Medicine   (Lithuania)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; TRANSCRIPTION FACTOR FRA 2; FOSL2 PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE; TSK1 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPSY; CAPILLARY DENSITY; CAPILLARY ENDOTHELIAL CELL; CARDIOMYOPATHY; CELL DIFFERENTIATION; CHRONIC GRAFT VERSUS HOST DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEART; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; MALE; MIDDLE AGED; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC SCLEROSIS; ANIMAL; BAGG ALBINO MOUSE; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CHRONIC DISEASE; COMPLICATION; DISEASE MODEL; GENETICS; GRAFT VERSUS HOST REACTION; HEART MUSCLE; METABOLISM; PATHOLOGY; RISK FACTOR; TRANSGENIC MOUSE;

ADULT; ANIMALS; APOPTOSIS; AUTOPSY; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FEMALE; FOS-RELATED ANTIGEN-2; GRAFT VS HOST DISEASE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MIDDLE AGED; MYOCARDIUM; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84922822849     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38942     Document Type: Article

References (46)

1. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y,. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012; 51: 1017-26.
2. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
3. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 139-53.
4. Hesselstrand R, Scheja A, Akesson A,. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 682-6.
5. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118: 2-10.
6. Steen VD, Medsger TA Jr., Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
7. Allanore Y, Meune C,. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin Exp Rheumatol 2010; 28; 5 Suppl: S48-53.
8. Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009; 68: 1878-84.
9. Kahan A, Coghlan G, McLaughlin V,. Cardiac complications of systemic sclerosis. Rheumatology (Oxford) 2009; 48 Suppl: iii45-8.
10. Allanore Y, Meune C, Kahan A,. Outcome measures for heart involvement in systemic sclerosis. Rheumatology (Oxford) 2008; 47 Suppl: v51-3.
11. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM,. Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction. Circulation 1976; 53: 483-90.
12. Tzelepis GE, Kelekis NL, Plastiras SC, Mitseas P, Economopoulos N, Kampolis C, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum 2007; 56: 3827-36.
13. Ngian GS, Sahhar J, Proudman SM, Stevens W, Wicks IP, Van Doornum S,. Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheum Dis 2012; 71: 1980-3.
14. Belloli L, Carlo-Stella N, Ciocia G, Chiti A, Massarotti M, Marasini B,. Myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 2008; 47: 1070-2.
15. Desai CS, Lee DC, Shah SJ,. Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol 2011; 23: 545-54.
16. Beyer C, Schett G, Distler O, Distler JH,. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010; 62: 2831-44.
17. Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun 2012; 3: 735.
18. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-24.
19. Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208: 961-72.
20. Dees C, Tomcik M, Palumbo-Zerr K, Distler A, Beyer C, Lang V, et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis Rheum 2012; 64: 3006-15.
21. Dees C, Zerr P, Tomcik M, Beyer C, Horn A, Akhmetshina A, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011; 63: 1396-404.
22. Horn A, Kireva T, Palumbo-Zerr K, Dees C, Tomcik M, Cordazzo C, et al. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis 2012; 71: 785-9.
23. Kronke G, Reich N, Scholtysek C, Akhmetshina A, Uderhardt S, Zerr P, et al. The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. Ann Rheum Dis 2012; 71: 1081-7.
24. Reich N, Tomcik M, Zerr P, Lang V, Dees C, Avouac J, et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis 2012; 71: 737-45.
25. Tomcik M, Zerr P, Pitkowski J, Palumbo-Zerr K, Avouac J, Distler O, et al. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis. Ann Rheum Dis 2014; 73: 1215-22.
26. Weingartner S, Zerr P, Tomcik M, Palumbo-Zerr K, Distler A, Dees C, et al. Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Ann Rheum Dis 2012; 71: 1895-9.
27. Zerr P, Distler A, Palumbo-Zerr K, Tomcik M, Vollath S, Dees C, et al. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. Am J Pathol 2012; 181: 1672-80.
28. Zerr P, Palumbo-Zerr K, Distler A, Tomcik M, Vollath S, Munoz LE, et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood 2012; 120: 2909-17.
29. Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A 2008; 105: 10525-30.
30. Maurer B, Busch N, Jungel A, Pileckyte M, Gay RE, Michel BA, et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009; 120: 2367-76.
31. Maurer B, Distler JH, Distler O,. The Fra-2 transgenic mouse model of systemic sclerosis. Vascul Pharmacol 2013; 58: 194-201.
32. Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G, et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012; 71: 1382-7.
33. Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zerr P, et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2010; 62: 280-90.
34. LeRoy EC, Medsger TA Jr., Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
35. Beyer C, Skapenko A, Distler A, Dees C, Reichert H, Munoz L, et al. Activation of pregnane X receptor inhibits experimental dermal fibrosis. Ann Rheum Dis 2013; 72: 621-5.
36. Palumbo-Zerr K, Horn A, Distler A, Zerr P, Dees C, Beyer C, et al. Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1. Ann Rheum Dis 2012; 71: 2051-4.
37. Khodzhigorova A, Distler A, Lang V, Dees C, Schneider H, Beyer C, et al. Inhibition of sumoylation prevents experimental fibrosis. Ann Rheum Dis 2012; 71: 1904-8.
38. Kramer M, Dees C, Huang J, Schlottmann I, Palumbo-Zerr K, Zerr P, et al. Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 2013; 72: 614-20.
39. Palumbo K, Zerr P, Tomcik M, Vollath S, Dees C, Akhmetshina A, et al. The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011; 70: 1320-6.
40. Akhmetshina A, Beer J, Zwerina K, Englbrecht M, Palumbo K, Dees C, et al. Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers. Arthritis Rheum 2010; 62: 1513-22.
41. Meune C, Vignaux O, Kahan A, Allanore Y,. Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 2010; 103: 46-52.
42. Osborn TG, Bashey RI, Moore TL, Fischer VW,. Collagenous abnormalities in the heart of the tight-skin mouse. J Mol Cell Cardiol 1987; 19: 581-7.
43. Xu H, Krolikowski JG, Jones DW, Ge ZD, Pagel PS, Pritchard KA Jr, et al. 4F decreases IRF5 expression and activation in hearts of tight skin mice. PLoS One 2012; 7: e52046.
44. Derrett-Smith EC, Dooley A, Khan K, Shi-wen X, Abraham D, Denton CP,. Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma. Arthritis Res Ther 2010; 12: R69.
45. Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176: 1983-98.
46. Manetti M, Rosa I, Milia AF, Guiducci S, Carmeliet P, Ibba-Manneschi L, et al. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis 2014; 73: 1700-9.